Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) CEO Michael A. Metzger Sells 13,288 Shares

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX - Get Free Report) CEO Michael A. Metzger sold 13,288 shares of the business's stock in a transaction on Monday, February 10th. The shares were sold at an average price of $15.50, for a total transaction of $205,964.00. Following the transaction, the chief executive officer now owns 300,121 shares in the company, valued at approximately $4,651,875.50. This represents a 4.24 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Syndax Pharmaceuticals Trading Down 1.1 %

Syndax Pharmaceuticals stock traded down $0.16 on Friday, reaching $14.92. 1,304,942 shares of the stock were exchanged, compared to its average volume of 2,238,445. The stock has a market cap of $1.27 billion, a PE ratio of -4.11 and a beta of 0.90. Syndax Pharmaceuticals, Inc. has a twelve month low of $12.06 and a twelve month high of $25.34. The firm has a fifty day moving average price of $13.88 and a two-hundred day moving average price of $17.11.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on SNDX shares. Citigroup boosted their price target on shares of Syndax Pharmaceuticals from $37.00 to $45.00 and gave the company a "buy" rating in a report on Tuesday, November 19th. StockNews.com lowered shares of Syndax Pharmaceuticals from a "hold" rating to a "sell" rating in a research note on Saturday, November 23rd. JPMorgan Chase & Co. lifted their price objective on shares of Syndax Pharmaceuticals from $33.00 to $38.00 and gave the company an "overweight" rating in a research note on Thursday, November 21st. HC Wainwright reaffirmed a "buy" rating and issued a $51.00 price objective on shares of Syndax Pharmaceuticals in a research note on Tuesday, December 10th. Finally, The Goldman Sachs Group lifted their price objective on shares of Syndax Pharmaceuticals from $30.00 to $33.00 and gave the company a "buy" rating in a research note on Thursday, November 7th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and nine have assigned a buy rating to the company's stock. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average price target of $36.20.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of SNDX. R Squared Ltd acquired a new position in shares of Syndax Pharmaceuticals during the fourth quarter valued at about $26,000. Values First Advisors Inc. acquired a new position in shares of Syndax Pharmaceuticals during the third quarter valued at about $30,000. Quantbot Technologies LP acquired a new position in shares of Syndax Pharmaceuticals during the third quarter valued at about $49,000. Mirae Asset Global Investments Co. Ltd. raised its position in shares of Syndax Pharmaceuticals by 21.3% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,078 shares of the company's stock valued at $58,000 after buying an additional 541 shares during the last quarter. Finally, Virtus ETF Advisers LLC raised its position in shares of Syndax Pharmaceuticals by 18.6% during the fourth quarter. Virtus ETF Advisers LLC now owns 5,278 shares of the company's stock valued at $70,000 after buying an additional 827 shares during the last quarter.

Syndax Pharmaceuticals Company Profile

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).